Janssen’s latest move against Amgen highlights shifting pharma patent strategies
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
GW’s recent ANDA lawsuit is a landmark moment, but will remain untypical of cannabis IP litigation
06 February 2023
The Dusselfdorf Regional Court has issued a sales ban against eight generics in the much-watched dispute
03 February 2023
Femtech entrepreneurs can take advantage of large empty spaces on the patent landscape to secure IP protection for their innovations
02 February 2023
President can now pick out foreign entities and subject them to a series of sanctions
01 February 2023
OUI’s patent policies were not unfair to spinout co-founder under consumer protection laws
31 January 2023
With Amgen’s biosimilar finally set to launch in the US, IAM looks back on arguably the most interesting set of pharma patent disputes in recent years
30 January 2023
The company has already secured lucrative settlements with Merck and Roche
26 January 2023
Director General José Sánchez Pérez meets with local lawyers to discuss enforcement and implementation of IP law
25 January 2023
ERS Genomics’ Michael Arciero shares his views on the Cas9 licensing landscape in an exclusive IAM interview
24 January 2023
The judgment is one of only a few decisions addressing the pre-emptive litigation defence
19 January 2023
Unlock unlimited access to all IAM content